Royal Bank of Canada Reiterates “Sector Perform” Rating for Catalent (NYSE:CTLT)

Royal Bank of Canada reiterated their sector perform rating on shares of Catalent (NYSE:CTLT) in a research note published on Thursday, Benzinga reports. They currently have a $63.50 price target on the stock.

A number of other equities research analysts also recently issued reports on CTLT. Barclays boosted their price target on Catalent from $47.00 to $63.00 and gave the company an equal weight rating in a research note on Friday, June 28th. Stephens reaffirmed an equal weight rating and set a $63.50 price objective on shares of Catalent in a research note on Thursday, April 4th. Finally, StockNews.com began coverage on shares of Catalent in a research note on Monday, July 8th. They set a sell rating for the company. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of Hold and a consensus price target of $55.65.

Catalent Stock Performance

NYSE:CTLT opened at $57.58 on Thursday. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.77 and a current ratio of 2.51. Catalent has a 52-week low of $31.80 and a 52-week high of $60.20. The firm has a market cap of $10.42 billion, a price-to-earnings ratio of -9.44, a PEG ratio of 2.38 and a beta of 1.16. The business’s fifty day moving average is $55.74 and its 200 day moving average is $54.91.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.36). Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. The company had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.11 billion. Research analysts predict that Catalent will post -0.17 EPS for the current year.

Insider Transactions at Catalent

In related news, CFO Matti Masanovich sold 2,993 shares of Catalent stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $56.74, for a total value of $169,822.82. Following the completion of the sale, the chief financial officer now directly owns 33,871 shares in the company, valued at $1,921,840.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CFO Matti Masanovich sold 2,993 shares of Catalent stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $56.74, for a total value of $169,822.82. Following the completion of the sale, the chief financial officer now directly owns 33,871 shares in the company, valued at $1,921,840.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ricky Hopson sold 1,401 shares of Catalent stock in a transaction dated Tuesday, June 4th. The shares were sold at an average price of $54.26, for a total value of $76,018.26. Following the completion of the sale, the insider now owns 20,617 shares of the company’s stock, valued at $1,118,678.42. The disclosure for this sale can be found here. Corporate insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Catalent

Several institutional investors and hedge funds have recently added to or reduced their stakes in CTLT. Vanguard Group Inc. grew its stake in Catalent by 1.8% in the third quarter. Vanguard Group Inc. now owns 20,468,027 shares of the company’s stock valued at $931,909,000 after purchasing an additional 365,648 shares during the last quarter. Exchange Traded Concepts LLC boosted its position in Catalent by 3,598.1% in the fourth quarter. Exchange Traded Concepts LLC now owns 25,443 shares of the company’s stock valued at $1,143,000 after buying an additional 24,755 shares during the last quarter. Harbor Capital Advisors Inc. lifted its holdings in Catalent by 8.8% in the fourth quarter. Harbor Capital Advisors Inc. now owns 10,860 shares of the company’s stock valued at $488,000 after acquiring an additional 874 shares during the period. Blue Zone Wealth Advisors LLC acquired a new position in Catalent in the fourth quarter valued at approximately $2,794,000. Finally, Dfpg Investments LLC lifted its holdings in Catalent by 16.0% in the fourth quarter. Dfpg Investments LLC now owns 18,254 shares of the company’s stock valued at $777,000 after acquiring an additional 2,520 shares during the period.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.